P0017 - Cross-State Comparative Assessment of Burden of Pancreatic Cancer in the United States and Its Trend From 1990-2021: A Benchmarking Systematic Analysis From the Global Burden of Disease Study 2021

Bhargav Koyani, MD¹, Himanshu Koyani, MBBS, MS², George Mathew Mukalil, MD³, Rutvik Raval, MBBS⁴, Shamitha Hejmadi, MBBS⁴, Lalitkumar Patel, MBBS⁵, Lovekumar Vala, MBBS⁶, Asmita Gera, MBBS⁷, Aditya Ahuja, MBBS⁸, Gunjan Kochhar, MBBS⁹, Jobby John, MBBS¹⁰, Hardik Dineshbhai. Desai, MBBS^11
1Saint Francis Hospital, Evanston, Evanston, IL; ²Sterling Hospital, Rajkot, Gujarat, India; ³Central Michigan University, Saginaw, MI; ⁴B.J. Medical College, Ahmedabad, Gujarat, India; ⁵Suburban Medical Center, Schaumburg, IL; ⁶Shantabaa Medical College and General Hospital, Amreli, Gujarat, India; ⁷Tianjin Medical University, Tianijin, Tianjin, China; ⁸Shrimann Hospital, Jalandhar, Punjab, India; ⁹Punjab Institute of Medical Sciences, Jalandhar, Punjab, India; ¹⁰Dr. Somervell Memorial CSI Medical College & Hospital Karakonam, Thiruvananthapuram, Kerala, India; ¹¹Gujarat Adani Institute of Medical Sciences, Ahmedabad, Gujarat, India

Introduction: Pancreatic Cancer (PC) ranks as the third leading cause of cancer-related deaths in the United States, following lung and colorectal cancers. This pioneering study provides a consistent and comparative estimation of the burden of PC in the US, including during the first two years of the COVID-19 pandemic, a period that posed significant challenges in the management of non-COVID-19 cases.

Methods: Using the Global Burden of Disease Study 2021 methodology, we estimated the incidence, prevalence, deaths, and disability-adjusted life years (DALYs) due to PC by age, sex, year, and location across the US from 1990-2021. Non-fatal health outcomes were estimated using DISMOD-MR 2.1, a meta-regression tool, while fatal health outcomes were calculated using the Cause of Death Ensemble Model (CODEm). Results were presented in absolute counts, unadjusted rate and age-standardized rates (ASR) (per 100,000 person-years).

Results: The total prevalence count of PC in the US increased from 25,549 (95% uncertainty interval: 24,171-26,355) in 1990 to 54,302 (50,464-56,688) in 2021. The total percentage change (TPC) in incidence count rose by 104%, followed by a 97% increase in deaths and a 90% increase in DALYs from 1990-2021. In terms of age-standardized rates, the incidence rate (ASIR) increased by 11%, the death rate (ASMR) by 6%, and the DALY rate (ASDALR) by 3% during the same period. Regionally, the highest increase in ASIR was observed in West Virginia at 34%, followed by Missouri at 29%. West Virginia also saw the highest rise in ASMR at 30%, with Iowa following at 26%. Conversely, the District of Columbia experienced the most significant decline in ASMR, decreasing by 14% from 1990 to 2021. Age-specific analysis showed that the 20-54 age group experienced the highest increase in incidence rate at 25%, followed by the 55+ age group at 10%. In terms of death rates, the 20-54 age group saw a 19% increase, while the 55+ age group observed a 6% rise. Gender-specific data indicated a higher overall disease burden in males compared to females. From 1990-2021, the TPC in incidence counts was 117% for males versus 92% for females; in deaths, 111% for males compared to 84% for females; and in DALYs, 98% for males versus 81% for females.

Discussion: Deaths due to PC accounted for 7.98% of all cancer related causalities in the US in 2021. These trends call for urgent public health interventions, including enhanced screening protocols and targeted education programs, particularly in high-risk areas.



Disclosures:


Bhargav Koyani, MD¹, Himanshu Koyani, MBBS, MS², George Mathew Mukalil, MD³, Rutvik Raval, MBBS⁴, Shamitha Hejmadi, MBBS⁴, Lalitkumar Patel, MBBS⁵, Lovekumar Vala, MBBS⁶, Asmita Gera, MBBS⁷, Aditya Ahuja, MBBS⁸, Gunjan Kochhar, MBBS⁹, Jobby John, MBBS¹⁰, Hardik Dineshbhai. Desai, MBBS¹¹. P0017 - Cross-State Comparative Assessment of Burden of Pancreatic Cancer in the United States and Its Trend From 1990-2021: A Benchmarking Systematic Analysis From the Global Burden of Disease Study 2021, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.